2022
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CBF, Malik AA, De la Cruz E, Jorge A, De los Santos M, Leon P, Breban MI, Billig K, Yildirim I, Pearson C, Downing R, Gagnon E, Muyombwe A, Razeq J, Campbell M, Ko AI, Omer SB, Grubaugh ND, Vermund SH, Iwasaki A. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nature Medicine 2022, 28: 481-485. PMID: 35051990, PMCID: PMC8938264, DOI: 10.1038/s41591-022-01705-6.Peer-Reviewed Original ResearchConceptsTwo-dose regimenOmicron variantVaccine boosterMRNA vaccinesNeutralization activityDelta variantTwo-dose mRNA vaccinesVirus-specific antibody levelsSARS-CoV-2 Omicron variantMRNA vaccine boosterNeutralization of OmicronNumerous spike mutationsSARS-CoV-2 DeltaPotent neutralization activityInfection-induced immunityCOVID-19 vaccineBNT162b2 boosterBooster vaccinationPrime vaccinationAntibody levelsAntibody titersHumoral immunityImmune escapeInactivated vaccinesVaccine
2017
A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primaryand booster vaccination of healthy Turkish infants and toddlers*
Ceyhan M, Yıldırım İ, Tezer H, Devrim İ, Feroldi E. A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primaryand booster vaccination of healthy Turkish infants and toddlers*. Turkish Journal Of Medical Sciences 2017, 47: 1247-1256. PMID: 29156870, DOI: 10.3906/sag-1609-62.Peer-Reviewed Original ResearchDTaP-IPVHB-PRPT vaccineT-BoostersPrimary seriesAnti-HBs seroprotectionLiquid DTaP-IPVT hexavalent vaccineOpen-label trialMIU/mLMonths of ageHealthy Turkish infantsAntibody persistenceBooster responseBooster vaccinationHB vaccinationControl vaccineHexavalent vaccineSeroconversion ratesTurkish infantsSeroprotectionVaccinePhase IIIParental reportsNoninferiority